Findings from a newly published randomized controlled trial offer surprising insights for the one in three adults at greater risk of heart disease because of prediabetes.

Pennington Biomedical researchers and their collaborators observed decreased activity in the brain regions responsible for ...

Wegovy, India’s first injectable semaglutide for chronic weight management, recorded Rs 2.54 crore in sales in June ...

A promising experimental drug is one more sign of the impending disruption the booming Chinese biotech industry could bring ...

Yet exercise can sometimes be deceptive. Years before starting Virta Health, while cofounding the real-estate company Trulia, ...

PRINCETON, NJ, USA I July 15, 2025 I Palatin Technologies, Inc. (OTCQB: PTNT), a biopharmaceutical company developing first-in-class medicines based on ...

Fractyl Health offers a high-risk, high-reward setup with a near-term binary catalyst in the REMAIN-1 cohort data expected Q3 ...

The game-changing weight loss jabs have ushered in a new era in the war on obesity, but have also been linked to other health ...

Preclinical study shows oral PL7737 agonist outperforms tirzepatide alone in rodent models, supporting Palatin’s plans for ...

Key Takeaways ・The weight-loss drug tirzepatide reduced both body fat and tumor growth in obese mice with breast cancer.

For adults with obesity treated with once-weekly tirzepatide, cardiometabolic risk factor improvements were positively ...

For adults with obesity or overweight, tirzepatide-linked improvements in cardiometabolic risk factors are associated with the degree of weight reduction.